MY ACCOUNT | NEWSLETTER |

Vetigenics collaborates with Merck to address chronic disease


Animal health biotechnology firm, Vetigenics, and pharmaceutical company division Merck & Co., Inc.'s Merch Animal Health. Out of the partnership, the two companies will seek to discover and create new therapeutic antibodies for pets' chronic diseases. 

The proprietary platform, Vetigenics' Canibody, is intended for dogs only and isolates genetic material called single chain variable fragments which can potentially be targeted for therapies. Because the therapies are created based on genetic material, the likelihood of immune reaction is greatly reduced.

"Vetigenics is thrilled that Merck Animal Health has expressed confidence in Vetigenics' Canibody Platform for the discovery of novel, entirely canine, antibody-based therapeutics," said Adriann Sax, co-founder, and chief executive officer of Vetigenics. "With our platform's highly differentiated qualities, most notably the complete species-specific antibody repertoire as well as the speed in which we can isolate high-value drug candidates, we are confident that combining the power of our platform with Merck Animal Health's exceptional development and commercialization capabilities will result in superior therapeutic antibodies to treat companion animals."

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Like1
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top